Express treatment of ovarian cancer and triple-negative breast cancer, innovative ADC therapy entered the clinic

▎The content team editor of WuXi AppTec today, ADC Therapeutics announced that its antibody-conjugated drug (ADC) ADCT-901, which targets kidney-associated antigen 1 (KAAG1), has completed the first patient administration in a phase 1 clinical trial.
Treatment of certain patients with advanced solid tumors (including treated ovarian cancer and triple-negative breast cancer) with high unfulfilled needs
.

ADCT-901 is produced by the anti-KAAG1 humanized monoclonal antibody, coupled with the cytotoxic molecule pyrrole benzodiazepine (PBD) dimer through a cathepsin cleavable linker
.

KAAG1 is a tumor-associated antigen that is highly expressed in most ovarian cancers and triple-negative breast cancers.
Its expression level in normal tissues is very limited, so it is an ideal target for ADC targeting
.

After ADCT-901 enters tumor cells, the released PBD can cross-link different DNA strands and hinder DNA replication and cell division
.

Image source: ADC Therapeutics official website.
This open label, dose escalation and expansion clinical trials will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-901
.

"We are very pleased to be able to quickly push this promising new antibody conjugate drug into clinical development
.

" said Dr.
Joseph Camardo, chief medical officer of ADC.
"KAAG1 is highly expressed in tumors where new therapeutic drugs are limited, including ovarian cancer and Triple-negative breast cancer
.

We look forward to evaluating ADCT-901 in a phase 1 clinical trial and finding the best dose
.

"Reference: [1] ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors.
Retrieved September 27, 2021, from https://ir.
adctherapeutics.
com/press-releases/press-release -details/2021/ADC-Therapeutics-Doses-First-Patient-in-Phase-1-Clinical-Trial-of-ADCT-901-in-Advanced-Solid-Tumors/default.
aspx Disclaimer: WuXi AppTec Content Team Focus on introducing the progress of global biomedical health research
.

This article is for information exchange purposes only.
The views in the article do not represent WuXi AppTec's position, nor do they support or oppose WuXi AppTec's views
in the
article .
This article is not a treatment plan recommendation
.

If you need a treatment plan, For guidance, please go to a regular hospital for treatment
.